Literature DB >> 33200170

Role of the rabbit whole-heart model for electrophysiologic safety pharmacology of non-cardiovascular drugs.

Christian Ellermann1, Julian Wolfes1, Lars Eckardt1, Gerrit Frommeyer1.   

Abstract

Plenty of non-cardiovascular drugs alter cardiac electrophysiology and may ultimately lead to life-threatening arrhythmias. In clinical practice, measuring the QT interval as a marker for the repolarization period is the most common tool to assess the electrophysiologic safety of drugs. However, the sole measurement of the QT interval may be insufficient to determine the proarrhythmic risk of non-cardiovascular agents. Several other markers are considered in pre-clinical safety testing to determine potential harm on cardiac electrophysiology. Besides measuring typical electrophysiologic parameters such as repolarization duration, whole-heart models allow the determination of potential predictors for proarrhythmia. Spatial and temporal heterogeneity as well as changes of shape of the action potential can be easily assessed. In addition, provocation manoeuvers (either by electrolyte imbalances or programmed pacing protocols) may induce sustained arrhythmias and thereby determine ventricular vulnerability to arrhythmias. Compared with the human heart, the rabbit heart possesses a similar distribution of ion currents that govern cardiac repolarization, resulting in a rectangular action potential configuration in both species. In addition, similar biophysical properties of rabbit and human cardiac ion channels lead to a comparable pharmacologic response in human and rabbit hearts. Of note, arrhythmia patterns resemble in both species due to the similar effective size of human and rabbit hearts. Thus, the rabbit heart is particularly suitable for testing the electrophysiologic safety of drugs. Several experimental setups have been developed for studying cardiac electrophysiology in rabbits, ranging from single cell to tissue preparations, whole-heart setups, and in vivo models. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Electrophysiological safety; Drug safety; Langendorff; Long QT syndrome; Pharmacology; QT interval; Rabbit; Torsade de pointes; Whole-heart model

Year:  2021        PMID: 33200170     DOI: 10.1093/europace/euaa288

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  1 in total

1.  Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models.

Authors:  Christian Ellermann; Jonas Brandt; Julian Wolfes; Kevin Willy; Felix K Wegner; Patrick Leitz; Philipp S Lange; Florian Reinke; Lars Eckardt; Gerrit Frommeyer
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.